藥明生物(02269.HK)倒升逾半成重越20天線
日前公布全年多賺近67%藥明生物(02269.HK)繼昨天逆市倒升後,今天低開跌至84.25元獲承接,掉頭節節向上兼重越10天及20天線(90.55元及91.7元),最高見93.4元,現造92.65元,倒升5.3%,為表現第二強藍籌,成交增至2,546萬股,涉資22.7億元。
藥明本周二收市後公布,去年純利按年升66.6%至16.89億元人民幣,每股盈利43分人民幣,總營收按年升41%至56.12億元,維持不派息。
恆指現造27,969,倒升51點或0.2%,成交額1,700億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.